Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 11:07 PM

Published 11/02/2009 by FierceBiotech


HGS's groundbreaking lupus drug promising in second Phase III

and its partner GlaxoSmithKline revealed that the high dose of their experimental lupus therapy demonstrated a statistically superior response compared to placebo in a second late-stage trial, laying the groundwork for an FDA marketing application.

Benlysta has helped transform HGS's...

Share this 

What others report on the same story

Positive Trial Results For Human Genome And Gla...
Human Genome Sciences Inc. (Nasdaq: HGSI) and GlaxoSmithKline (NYSE: GSK) announced positive results for its lupus drug treatment and planned to get FDA approval ... - [11/03/2009 - gfn.com]
Human Genome Sciences Shares Rose 33% After Mee...
11/2/2009 - Human Genome Sciences (NASDAQ:HGSI) shares rose nearly 33% after the company and GlaxoSmithKline (NYSE:GSK) announced that BENLYSTA met the primary endpoint ... - [11/02/2009 - Individual.com]
Innovative Drug Companies Headline the Gainers
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs ... - [11/02/2009 - Long Investment Ideas from Seeking Alpha]
Human Genome Sciences and GlaxoSmithKline Annou... - [11/02/2009 - Market Wire via MSN Money]
Human Genome, GSK see progress with lupus drug - [11/02/2009 - MarketWatch]
Lupus Drug Shows Promise in New Trial - [11/02/2009 - New York Times]
Promise of a New Lupus Treatment is a Groundbre... - [11/02/2009 - Business Wire]
Market Report -- In Play (HGSI) - [11/02/2009 - Briefing.com via MSN Money]
Human Genome, GSK See Progress With Lupus Drug - [11/02/2009 - FOXBusiness.com]
Promise of a New Lupus Treatment is a Groundbre... - [11/02/2009 - CNBC]
1 2 3 4 5 6 7

Quotes

...half of 2010. "Benlysta is poised to capture a multibillion-dollar opportunity for lupus" Joseph Schwartz, an...
HGS's groundbreaking lupus drug promising in second Phase III [FierceBiotech - 11/02/2009]
...the low dose. "The BLISS-76 results confirm our view that Benlysta has the potential to become the first new approved drug in decades for people living with systemic lupus" said Watkins...
HGS's groundbreaking lupus drug promising in second Phase III [FierceBiotech - 11/02/2009]
...said Watkins. "The lupus community has waited for decades for one positive phase three trial of an investigative drug developed for lupus" Dr. Joan T Merrill...
HGS's groundbreaking lupus drug promising in second Phase III [FierceBiotech - 11/02/2009]

Related Stories

First Reported 11/02/2009 - Updated 11/02/2009 - 6 Documents
Humana Inc - Click to view image in its original context
Humana Inc
Stocks Land on Green After Roller Coaster Day
There's No Business Like FOX BusinessAfter another roller coaster day full of rallies and selloffs, the markets closed in positive territory on Monday, bouncing back from their worst day in six months thanks to a trifecta of upbeat economic reports.Today's ... [FOXBusiness.com - 11/02/2009]
First Reported 11/03/2009 - Updated 11/03/2009 - 1 Documents (in Health)
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
Health Highlights: Nov. 3, 2009
Cereal's 'Immunity' Claim Outrages ExpertsHealth and nutrition experts are attacking Kellogg for claims that one of its cereals benefits children's immune systems because it contains increased levels of vitamins A, C and E.Bold lettering on the front ... [Forbes.com - 11/03/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Could We Be On the Verge of a New Drug to Treat... [Scientific American - Observations - 11/03/2009]
Systemic lupus is the most common form of the autoimmune disease, lupus , which afflicts about 5 million people worldwide and causes a slew of symptoms including ...
Innovative Drug Companies Headline the Gainers [Healthcare Sector and Stocks Analysis from Seek ... - 11/02/2009]
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs ...
Innovative Drug Companies Headline the Gainers [Long Investment Ideas from Seeking Alpha - 11/02/2009]
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs ...
Trial Results Bode Well for Human Genome Sciences [Healthcare Sector and Stocks Analysis from Seek ... - 11/02/2009]
EP Vantage submits:The high hopes that both the market and sufferers from lupus hold for Human Genome Sciences' (HGSI) lead drug, Benlysta, showed no signs of being ...
Lower Third Quarter Loss for Human Genome [Healthcare Sector and Stocks Analysis from Seek ... - 11/05/2009]
Zacks.com submits: Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. ...
1 2

Audio/Video

sort by: Date | Relevance
The week ahead with Jack and Jack [Reuters Video: Business - 10/30/2009]
Watkins Says Benlysta Could Be Available by End... [Bloomberg - YouTube - 11/02/2009]
1

  •  
  •  
  •